NOD2 and systemic inflammatory response syndrome: One AAS patient, who developed SIRS at POD1, had very high levels of NOD2 agonist (20 to 40 fold increase of NF-κB activation) during the whole observational period starting at time point T2, which led to a statistically significant difference in the values between the two groups at T2.